Abstract
Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a commonly used one-step modality for peritoneal surface malignancies. Despite the gain in popularity and effectiveness, HIPEC is still associated with significant post-operative morbidity and mortality. Liver failure, following HIPEC surgery, which does not involve major liver resection has not been well defined or reported. Hence, we report a case of liver failure in a 51-year-old lady, with recurrent carcinoma ovary, who underwent cytoreductive surgery followed by HIPEC and the potential multifactorial causes that could have caused it.
Highlights
The novel technique of cytoreductive surgery (CRS) was first described by Sugarbaker [1]
Despite the increased use and better understanding of physiology associated with this unique surgical technique, the morbidity associated with it remains as high as 50% in certain series [2]
We describe a rare case of acute hepatic failure post CRS and hyperthermic intraperitoneal chemotherapy (HIPEC)
Summary
The novel technique of cytoreductive surgery (CRS) was first described by Sugarbaker [1]. Histopathological examination (HPE) revealed a borderline mucinous tumour with invasive deposits in the right parametrium and omentum and features of pseudomyxoma peritonei She received no adjuvant treatment in view of HPE showing pseudomyxoma. A contrast enhanced CT (CECT) scan revealed omentum, splenic and liver sub-capsular deposits. She was subsequently referred to our centre for secondary cytoreduction. Her case was further evaluated, optimised, and discussed in a multidisciplinary tumour board and after optimisation was planned for surgery She underwent a diagnostic laparoscopy followed by cytoreductive surgery, which included anterior resection, right hemicolectomy, splenectomy, wedge excision of left lobe of liver, cholecystectomy and total peritonectomy with HIPEC. POD: Post-operative Day; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; ALP: Alkaline Phosphatase; PT: Prothrombin Time; INR: International Normalised Ratio
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
